Inmune Bio (INMB) Debt to Equity (2021 - 2024)
Inmune Bio (INMB) has disclosed Debt to Equity for 4 consecutive years, with $0.13 as the latest value for Q3 2024.
- Quarterly Debt to Equity fell 54.16% to $0.13 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $0.13 through Sep 2024, down 54.16% year-over-year, with the annual reading at $0.27 for FY2023, 8.66% up from the prior year.
- Debt to Equity hit $0.13 in Q3 2024 for Inmune Bio, down from $0.28 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.53 in Q1 2024 to a low of $0.13 in Q3 2024.
- Historically, Debt to Equity has averaged $0.26 across 4 years, with a median of $0.26 in 2023.
- Biggest YoY gain for Debt to Equity was 98.45% in 2024; the steepest drop was 54.16% in 2024.
- Year by year, Debt to Equity stood at $0.18 in 2021, then surged by 35.68% to $0.24 in 2022, then rose by 8.66% to $0.27 in 2023, then plummeted by 51.4% to $0.13 in 2024.
- Business Quant data shows Debt to Equity for INMB at $0.13 in Q3 2024, $0.28 in Q2 2024, and $0.53 in Q1 2024.